昌紅科技(300151.SZ):控股子公司擬以資產抵押申請4億元借款 用於“高分子醫療耗材產業園”建設
格隆匯9月12日丨昌紅科技(300151.SZ)公佈,公司控股子公司浙江柏明勝擬向中國銀行申請人民幣4億元的借款(貸款期限為5年),用於“高分子醫療耗材產業園”項目建設,浙江柏明勝將根據項目進度,分期向銀行提出借款申請,實際的使用資金量以及提取資金時間尚不確定。按照銀行要求,此次借款需由浙江柏明勝提供最高額抵押擔保,並簽訂編號為“上公21586291897人抵001”的擔保合同。浙江柏明勝將其位於杭州灣上虞經濟技術開發區東二區的自有土地(評估價值6032.3萬元,編號:浙2021紹興市上虞區不動產權第0010483號)抵押給中國銀行。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.